- Home
- MAIA vs ANVS Comparison
MAIA vs ANVS Comparison
Compare MAIA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ANVS
- Stock Information
- Founded
- MAIA 2018
- ANVS 2008
- Country
- MAIA United States
- ANVS United States
- Employees
- MAIA N/A
- ANVS N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- ANVS Health Care
- Exchange
- MAIA Nasdaq
- ANVS Nasdaq
- Market Cap
- MAIA 62.4M
- ANVS 110.4M
- IPO Year
- MAIA 2022
- ANVS 2020
- Fundamental
- Price
- MAIA $2.82
- ANVS $9.64
- Analyst Decision
- MAIA
- ANVS Strong Buy
- Analyst Count
- MAIA 0
- ANVS 6
- Target Price
- MAIA N/A
- ANVS $29.67
- AVG Volume (30 Days)
- MAIA 60.0K
- ANVS 341.4K
- Earning Date
- MAIA 11-05-2024
- ANVS 11-06-2024
- Dividend Yield
- MAIA N/A
- ANVS N/A
- EPS Growth
- MAIA N/A
- ANVS N/A
- EPS
- MAIA N/A
- ANVS N/A
- Revenue
- MAIA N/A
- ANVS N/A
- Revenue This Year
- MAIA N/A
- ANVS N/A
- Revenue Next Year
- MAIA N/A
- ANVS N/A
- P/E Ratio
- MAIA N/A
- ANVS N/A
- Revenue Growth
- MAIA N/A
- ANVS N/A
- 52 Week Low
- MAIA $0.82
- ANVS $4.53
- 52 Week High
- MAIA $5.99
- ANVS $22.49
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- ANVS 58.70
- Support Level
- MAIA $2.36
- ANVS $9.00
- Resistance Level
- MAIA $2.72
- ANVS $10.54
- Average True Range (ATR)
- MAIA 0.22
- ANVS 0.81
- MACD
- MAIA 0.02
- ANVS 0.12
- Stochastic Oscillator
- MAIA 72.28
- ANVS 74.57
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.